Logo
x

Search

Subscribe Now

Olumiant

PharmaShots Interview: Eli Lilly's Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021

PharmaShots Interview: Eli Lilly's Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021

  • August 2, 2021
Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

  • March 11, 2021
Lilly and Incyte's Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time

Lilly and Incyte's Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time

  • October 9, 2020
Lilly's Olumiant (baricitinib) Receives CHMP's Positive Opinion for Moderate to Severe Atopic Dermatitis

Lilly's Olumiant (baricitinib) Receives CHMP's Positive Opinion for Moderate to Severe Atopic Dermatitis

  • September 21, 2020
Eli Lilly and Incyte's Olumiant + Gilead's Veklury Reduce Time to Recovery in Hospitalized Patients with COVID-19

Eli Lilly and Incyte's Olumiant + Gilead's Veklury Reduce Time to Recovery in Hospitalized Patients with COVID-19

  • September 15, 2020
Lilly Reveals New Data for Olumiant (baricitinib) to Treat Rheumatoid Arthritis and Systemic Lupus Erythematosus #EULAR

Lilly Reveals New Data for Olumiant (baricitinib) to Treat Rheumatoid Arthritis and Systemic Lupus Erythematosus #EULAR

  • June 3, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.